Changeflow GovPing Pharma & Drug Safety MDMA Prodrug Carbamate Compounds - Apoapsis Hol...
Routine Rule Added Final

MDMA Prodrug Carbamate Compounds - Apoapsis Holdings

Favicon for changeflow.com USPTO Patent Grants - Organic Chemistry (C07D)
Published
Detected
Email

Summary

USPTO granted Patent US12600708B2 to Apoapsis Holdings, LLC for novel MDMA prodrug carbamate compounds and synthesis methods. The patent covers 19 claims for compounds that are enzymatically cleaved in vivo to produce low-toxicity alcohols. The inventors include Denton W. Hoyer, Robert F. Roscow, Rong Ling, and Chuanjun Gao.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

USPTO granted a new patent for MDMA prodrug carbamate compounds. The patent covers novel compounds that can be activated in vivo as prodrugs, with enzymatic cleavage producing alcohols of low toxicity that are well tolerated in humans.

Patent holders and licensees may benefit from the exclusivity granted by this patent. Researchers and pharmaceutical companies developing MDMA-based therapies should monitor this patent when planning drug development programs involving prodrug approaches.

What to do next

  1. Monitor patent portfolio for potential licensing opportunities
  2. Review patent claims for research and development implications

Archived snapshot

Apr 14, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Grants

Prodrug compounds of 3,4-methylenedioxymethamphetamine (MDMA) and methods of synthesizing the same

Grant US12600708B2 Kind: B2 Apr 14, 2026

Assignee

Apoapsis Holdings, LLC

Inventors

Denton W. Hoyer, Robert F. Roscow, Rong Ling, Chuanjun Gao

Abstract

The present invention includes a novel class of MDMA carbamates that can be activated in vivo as prodrugs. The MDMA prodrugs of the invention are enzymatically cleaved in vivo and produce alcohols of low toxicity that are well tolerated and metabolized in humans.

CPC Classifications

C07D 317/58 C07D 327/04

Filing Date

2023-07-26

Application No.

18226767

Claims

19

View original document →

Get daily alerts for USPTO Patent Grants - Organic Chemistry (C07D)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 14th, 2026
Instrument
Rule
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
US12600708B2

Who this affects

Applies to
Pharmaceutical companies Drug manufacturers Investors
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent granting Drug development Pharmaceutical research
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Public Health

Get alerts for this source

We'll email you when USPTO Patent Grants - Organic Chemistry (C07D) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!